142 related articles for article (PubMed ID: 36565051)
1. Trends in prevalence of probable fibrotic non-alcoholic steatohepatitis in the United States, 1999-2016.
Ciardullo S; Perseghin G
Liver Int; 2023 Feb; 43(2):340-344. PubMed ID: 36565051
[TBL] [Abstract][Full Text] [Related]
2. Noninvasive identification of probable fibrotic nonalcoholic steatohepatitis across the spectrum of glucose tolerance in the United States.
Ciardullo S; Carbone M; Invernizzi P; Perseghin G
Diabetes Res Clin Pract; 2023 May; 199():110679. PubMed ID: 37094749
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of Prediabetes and Type 2 Diabetes in Children With Nonalcoholic Fatty Liver Disease.
Newton KP; Hou J; Crimmins NA; Lavine JE; Barlow SE; Xanthakos SA; Africa J; Behling C; Donithan M; Clark JM; Schwimmer JB;
JAMA Pediatr; 2016 Oct; 170(10):e161971. PubMed ID: 27478956
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of prediabetes and diabetes in children and adolescents with biopsy-proven non-alcoholic fatty liver disease.
Nobili V; Mantovani A; Cianfarani S; Alisi A; Mosca A; Sartorelli MR; Maffeis C; Loomba R; Byrne CD; Targher G
J Hepatol; 2019 Oct; 71(4):802-810. PubMed ID: 31279904
[TBL] [Abstract][Full Text] [Related]
6. Fibrotic NASH in Individuals with Obesity: a Cross-sectional Analysis of the Prevalence of this Significant Milestone of Disease Progression and Accuracy of a Non-invasive Marker for its Screening.
de Souza Echeverria L; Mounzer DLS; Gestic MA; Utrini MP; Chaim FDM; Callejas-Neto F; Chaim EA; Cazzo E
Obes Surg; 2024 Feb; 34(2):389-395. PubMed ID: 38110785
[TBL] [Abstract][Full Text] [Related]
7. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.
Estes C; Anstee QM; Arias-Loste MT; Bantel H; Bellentani S; Caballeria J; Colombo M; Craxi A; Crespo J; Day CP; Eguchi Y; Geier A; Kondili LA; Kroy DC; Lazarus JV; Loomba R; Manns MP; Marchesini G; Nakajima A; Negro F; Petta S; Ratziu V; Romero-Gomez M; Sanyal A; Schattenberg JM; Tacke F; Tanaka J; Trautwein C; Wei L; Zeuzem S; Razavi H
J Hepatol; 2018 Oct; 69(4):896-904. PubMed ID: 29886156
[TBL] [Abstract][Full Text] [Related]
8. The epidemiology of non-alcoholic steatohepatitis (NASH) in the United States between 2010-2020: a population-based study.
Hamid O; Eltelbany A; Mohammed A; Alsabbagh Alchirazi K; Trakroo S; Asaad I
Ann Hepatol; 2022; 27(5):100727. PubMed ID: 35700934
[TBL] [Abstract][Full Text] [Related]
9. Epidemiology of chronic liver diseases in the USA in the past three decades.
Younossi ZM; Stepanova M; Younossi Y; Golabi P; Mishra A; Rafiq N; Henry L
Gut; 2020 Mar; 69(3):564-568. PubMed ID: 31366455
[TBL] [Abstract][Full Text] [Related]
10. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis.
Younossi ZM; Golabi P; de Avila L; Paik JM; Srishord M; Fukui N; Qiu Y; Burns L; Afendy A; Nader F
J Hepatol; 2019 Oct; 71(4):793-801. PubMed ID: 31279902
[TBL] [Abstract][Full Text] [Related]
11. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort.
Harrison SA; Gawrieh S; Roberts K; Lisanti CJ; Schwope RB; Cebe KM; Paradis V; Bedossa P; Aldridge Whitehead JM; Labourdette A; Miette V; Neubauer S; Fournier C; Paredes AH; Alkhouri N
J Hepatol; 2021 Aug; 75(2):284-291. PubMed ID: 33746083
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of High-risk Nonalcoholic Steatohepatitis (NASH) in the United States: Results From NHANES 2017-2018.
Vilar-Gomez E; Vuppalanchi R; Mladenovic A; Samala N; Gawrieh S; Newsome PN; Chalasani N
Clin Gastroenterol Hepatol; 2023 Jan; 21(1):115-124.e7. PubMed ID: 34958922
[TBL] [Abstract][Full Text] [Related]
13. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
[TBL] [Abstract][Full Text] [Related]
14. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.
Bazick J; Donithan M; Neuschwander-Tetri BA; Kleiner D; Brunt EM; Wilson L; Doo E; Lavine J; Tonascia J; Loomba R
Diabetes Care; 2015 Jul; 38(7):1347-55. PubMed ID: 25887357
[TBL] [Abstract][Full Text] [Related]
15. Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments.
Roeb E; Geier A
Z Gastroenterol; 2019 Apr; 57(4):508-517. PubMed ID: 30965381
[TBL] [Abstract][Full Text] [Related]
16. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis.
Quek J; Chan KE; Wong ZY; Tan C; Tan B; Lim WH; Tan DJH; Tang ASP; Tay P; Xiao J; Yong JN; Zeng RW; Chew NWS; Nah B; Kulkarni A; Siddiqui MS; Dan YY; Wong VW; Sanyal AJ; Noureddin M; Muthiah M; Ng CH
Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):20-30. PubMed ID: 36400097
[TBL] [Abstract][Full Text] [Related]
17. Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease.
Barb D; Repetto EM; Stokes ME; Shankar SS; Cusi K
Obesity (Silver Spring); 2021 Nov; 29(11):1950-1960. PubMed ID: 34553836
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of non alcoholic fatty liver and Non alcoholic Steatohepatitis in Peshawar Cantonment, Khyber Pakhtunkhwa, Pakistan.
Shah AS; Khan S; Rahim H; Chishti KA; Khan AG
Pak J Pharm Sci; 2018 Jan; 31(1):193-198. PubMed ID: 29348103
[TBL] [Abstract][Full Text] [Related]
19. High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels.
Portillo-Sanchez P; Bril F; Maximos M; Lomonaco R; Biernacki D; Orsak B; Subbarayan S; Webb A; Hecht J; Cusi K
J Clin Endocrinol Metab; 2015 Jun; 100(6):2231-8. PubMed ID: 25885947
[TBL] [Abstract][Full Text] [Related]
20. [Prevalence and clinical features of non-alcoholic steatohepatitis in a hypertensive population].
García-Carretero R; Barquero-Pérez O; Mora-Jiménez I; Soguero-Ruiz C; Goya-Esteban R; Rodríguez-Castro C; Ramos-López J
Hipertens Riesgo Vasc; 2019; 36(3):130-136. PubMed ID: 30655210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
